phrykt

Protagonist Therapeutics, Inc (PTGX): who owns it and who trades it

As of Nov 12, 2026, PTGX insiders reported 36 open-market sales worth $87.7M and no purchases in the last 12 months, with 59% of the sale value made under pre-set 10b5-1 plans. The largest seller was Dinesh V Ph D Patel (CEO), with $53.1M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Protagonist Therapeutics

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns PTGX

342 funds and institutions reported PTGX shares worth $9.4B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 16.0%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.16.0%
Farallon Capital Management, L.l.c.9.9%
Rtw Investments, LP7.9%
Vanguard Portfolio Management LLC5.6%
Wellington Management Group LLP5.3%
UBS Group AG5.3%
State Street Corp5.2%
Vanguard Capital Management LLC4.4%
Johnson & Johnson3.8%
Invesco Ltd.3.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.10.31M16.03%$1.3B+5%
Farallon Capital Management, L.l.c.6.35M9.87%$778MNo change
Rtw Investments, LP5.06M7.87%$620MNo change
Vanguard Portfolio Management LLC3.63M5.64%$445M+4%
Wellington Management Group LLP3.42M5.31%$419M-5%
UBS Group AG3.40M5.29%$417M-34%
State Street Corp3.32M5.16%$407M+7%
Vanguard Capital Management LLC2.85M4.44%$350M+2%
Johnson & Johnson2.45M3.81%$300MNo change
Invesco Ltd.2.34M3.64%$287M+8%
T. Rowe Price Associates2.15M3.34%$264M+29%
Jupiter Topco LLC2.13M3.31%$261M–
Geode Capital Management, LLC1.74M2.71%$213M+4%
Woodline Partners LP1.41M2.20%$173MNo change
Bank of America Corp1.32M2.06%$162M+2%
Jennison Associates LLC1.15M1.79%$141M+7%
Perceptive Advisors LLC981,8791.53%$120M-20%
ADAR1 Capital Management, LLC960,8631.49%$118M-3%
Morgan Stanley905,9921.41%$111M-11%
Alyeska Investment Group, L.P.889,2981.38%$109M+50%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, PTGX insiders reported $0 of open-market purchases and $87.7M of sales. 59% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$87.7M
36 trades, 7 people
Sales under a 10b5-1 plan
59%
Share of sale value
Latest trade
Sep 30, 2026
Filed Oct 2, 2026

Purchases and sales by month

$26.6M$26.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 30, 2026Asif AliCFOSale plan12,595$141.77$1.8MForm 4
Sep 30, 2026Asif AliCFOSale plan46,034$141.78$6.5MForm 4
Sep 10, 2026Dinesh V Ph D PatelCEOSale plan7,278$144.10$1MForm 4
Sep 9, 2026Dinesh V Ph D PatelCEOSale plan63,548$146.18$9.3MForm 4
Sep 8, 2026Dinesh V Ph D PatelCEOSale plan54,174$145.87$7.9MForm 4
Aug 11, 2026Dinesh V Ph D PatelCEOSale plan34,239$148.52$5.1MForm 4
Aug 10, 2026Dinesh V Ph D PatelCEOSale plan65,761$149.11$9.8MForm 4
Jun 23, 2026William D. WaddillDirectorSale plan9,000$117.94$1.1MForm 4
Jun 10, 2026William D. WaddillDirectorSale plan9,000$107.68$969KForm 4
May 29, 2026William D. WaddillDirectorSale plan9,000$99.64$897KForm 4
May 12, 2026Dinesh V Ph D PatelCEOSale plan75,000$100.12$7.5MForm 4
May 8, 2026Bryan GiraudoDirectorSale5,130$100.00$513KForm 4
May 8, 2026Bryan GiraudoDirectorSale6,000$100.00$600KForm 4
May 7, 2026Bryan GiraudoDirectorSale36,000$100.14$3.6MForm 4
May 7, 2026Bryan GiraudoDirectorSale12,000$100.07$1.2MForm 4
Apr 20, 2026Asif AliCFOSale1,750$105.47$185KForm 4
Mar 26, 2026Arturo Md MolinaChief Medical OfficerSale15,000$104.79$1.6MForm 4
Mar 26, 2026Harold E SelickDirectorSale24,000$105.00$2.5MForm 4
Mar 26, 2026Asif AliCFOSale24,765$104.24$2.6MForm 4
Mar 25, 2026Dinesh V Ph D PatelCEOSale54,641$101.00$5.5MForm 4
Mar 24, 2026Dinesh V Ph D PatelCEOSale59$101.00$6KForm 4
Feb 17, 2026Lewis T WilliamsDirectorSale18,000$82.42$1.5MForm 4
Feb 6, 2026William D. WaddillDirectorSale20,000$83.68$1.7MForm 4
Jan 27, 2026Dinesh V Ph D PatelCEOSale4,068$83.19$338KForm 4
Jan 27, 2026Asif AliCFOSale28,000$83.13$2.3MForm 4
Jan 27, 2026Asif AliCFOSale18,203$83.14$1.5MForm 4
Jan 27, 2026Arturo Md MolinaChief Medical OfficerSale5,000$82.00$410KForm 4
Jan 26, 2026Dinesh V Ph D PatelCEOSale10,685$84.00$898KForm 4
Jan 26, 2026Dinesh V Ph D PatelCEOSale14,205$84.05$1.2MForm 4
Jan 26, 2026Arturo Md MolinaChief Medical OfficerSale5,000$82.28$411KForm 4
Jan 23, 2026Dinesh V Ph D PatelCEOSale19,315$84.59$1.6MForm 4
Jan 23, 2026Arturo Md MolinaChief Medical OfficerSale13,151$82.42$1.1MForm 4
Jan 20, 2026Arturo Md MolinaChief Medical OfficerSale9,514$82.48$785KForm 4
Jan 20, 2026Dinesh V Ph D PatelCEOSale34,438$82.48$2.8MForm 4
Jan 20, 2026Asif AliCFOSale8,588$82.48$708KForm 4
Nov 17, 2025Arturo Md MolinaChief Medical OfficerSale2,712$84.77$230KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Dinesh V Ph D PatelPresident and CEO, Director–$53.1MSep 10, 2026
Asif AliChief Financial Officer–$15.6MSep 30, 2026
Bryan GiraudoDirector–$5.9MMay 8, 2026
William D. WaddillDirector–$4.6MJun 23, 2026
Arturo Md MolinaChief Medical Officer–$4.5MMar 26, 2026
Harold E SelickDirector–$2.5MMar 26, 2026
Lewis T WilliamsDirector–$1.5MFeb 17, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PTGX short interest

High short interest. 15.8% of PTGX shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 40%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 10.24M PTGX shares were sold short, 15.8% of the shares outstanding, down 0.5% from the report before. At the average daily volume of 606,261 shares, buying them all back would take about 16.9 trading days (days to cover).

Shares short, % of all shares

15.8%May 15Oct 3016.6%

Days to cover

16.9May 15Oct 3018.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202610.24M15.83%-1%606,26116.9
Oct 15, 202610.30M15.91%+10%856,44812.0
Sep 30, 20269.35M14.44%+15%813,30011.5
Sep 15, 20268.14M12.58%+6%538,02315.1
Aug 31, 20267.71M11.92%-1%502,80215.3
Aug 14, 20267.79M12.04%+3%474,58116.4
Jul 31, 20267.54M11.66%-9%530,73914.2
Jul 15, 20268.29M12.89%+8%870,3749.5
Jun 30, 20267.69M11.96%-0%1.07M7.2
Jun 15, 20267.73M12.02%+4%666,63611.6
May 29, 20267.41M11.52%+2%440,77616.8
May 15, 20267.29M11.34%-3%571,83112.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Protagonist Therapeutics company events

Protagonist Therapeutics filed 6 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Aug 5, 2026ResultsReleased financial results. Filing
  3. Jun 18, 2026LeadershipDeparture of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
  4. May 5, 2026ResultsReleased financial results. Filing
  5. Feb 25, 2026ResultsReleased financial results. Filing
  6. Jan 12, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Protagonist Therapeutics financials

Famous investors that hold PTGX

2 of the 50 well-known investors we track reported holding PTGX in their latest 13F filing. The largest position is Ken Fisher's, worth $23.7M.

FundQuarterSharesValueOf portfolioChange
Ken Fisher · Fisher Asset ManagementQ3 2026168,373$23.7M0.0%-1%
Jim Simons · Renaissance TechnologiesQ3 202676,967$10.8M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named PTGX in the last 120 days.

FiledHolderFormStake
Oct 27, 2026BlackRock, Inc.13G/A15.2%
Oct 27, 2026BlackRock, Inc.13G/A15.2%

Questions about Protagonist Therapeutics, Inc (PTGX) stock

Who owns the most PTGX stock?

The largest reported owner of Protagonist Therapeutics, Inc (PTGX) is BlackRock, Inc., with 16.0% of the company. In total, 342 funds and institutions reported holding PTGX at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are PTGX insiders buying or selling?

In the last 12 months, PTGX insiders reported no open-market purchases and 36 sales worth $87.7M. The latest trade was on Sep 30, 2026. See every trade.

What is the short interest in PTGX?

As of Oct 30, 2026, 10.24M PTGX shares were sold short, 15.8% of the shares outstanding, down 0.5% from the report before. At the average daily volume of 606,261 shares, buying them all back would take about 16.9 trading days (days to cover). See the history.

Which famous investors hold PTGX?

2 of the 50 well-known investors we track reported PTGX in their latest 13F filing, including Ken Fisher, Jim Simons. The largest position is worth $23.7M. See all holders.

Executive pay

Protagonist Therapeutics's chief executive was paid a total of $12.9M for the year ended Dec 31, 2025, up 36% from $9.5M the year before. In the last 12 months, Protagonist Therapeutics's executives and directors bought no stock on the open market and sold $87.7M.

Chief executive, total pay$12.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$46.1MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3.7MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.